Happy Thursday everyone. I'm currently in the air and will be landing in NYC soon. I'm having dinner with JC and friends and then drinks with Patrick and some of the guys on the analyst team. I'll be making my rounds, visiting family and friends through the weekend, so let me know if you're in town. Now, let's talk about stocks quickly. The market is firing on all cylinders. It's becoming more and more of an everything rally everyday. The hardest part about navigating this kind of bull market environment is focusing on the right areas. For this reason, we've been pumping out deep dives over the past few weeks- focusing on the industry groups and themes we're most bullish on. Today, we're bringing you biotech. Hope you enjoy it!👇 |
|
|
Biotech has been one of the worst-performing industry groups this cycle. Investors have got used to it as these stocks have been dead money for much of the past decade.
While speculative growth and risk-on areas of the market are powering higher, biotech is stuck in the same range it has been in for years.
And, I know what you're thinking. It's the fundamental headwinds—an unfriendly administration under RFK Jr and elevated interest rates—but here we let price action speak.
And right now, the action is suggesting it's time to buy the biotechs. |
The S&P Biotech ETF $XBI just cleared the VWAP anchored to last November's post-election highs—a dynamic resistance level that has capped every rally attempt since.
As long as bios can stick the landing, the risk/reward in the short-to-medium term tilts to the upside.
I want to jump this breakout in anticipation of a primary trend reversal. |
You can see a textbook multi-year rounding bottom when you zoom out.
We can use a 2-step confirmation process for scaling in or increasing exposure to the space.
The prior-cycle high VWAP around 91 is the first level.
The 38% retracement and pivot highs at 105 mark the ultimate confirmation that a new uptrend is underway.
I'm going to add more and more exposure as we take these levels out.
But I'm not doing it via the index. As usual, I want to express our thesis through individual biotech stocks… the ones showing relative strength and momentum.
Let's talk about some of the leaders now.
Here's our Biotech, Genomics, and Diagnostics leadership scan, sorted by distance to new highs: |
This is a space where alpha can always be found, regardless of what's going on with the rest of the market. But if the complex finally wakes from this long slumber, it will create an industry-wide tailwind… and picking winners will become easier. When biotech moves, the leaders don't crawl—they explode. I want to be ready to capture that surge. I'm trading it with a nice mix of names along the cap scale… and of course, a few squeeze candidates. If you're not a member of ASC Premium and want access to the trade ideas from this post, join us risk-free. |
Here's What You Missed Yesterday If you missed yesterday's crypto breakout session — no worries, the replay's up now.
This move's the real deal, and it's picking up speed.
Watch the replay here.
Louis Sykes — my buddy who's been all over this — breaks down what's happening and what's next. You'll see:
→ Bitcoin dominance starting to crack
→ Big players jumping in (but not where you'd expect)
→ Altcoins shaping up like junior miners back in the early 2000s
→ Trade ideas, setups, and how to handle risk right now
If you're in the crypto game, this is worth your time.
|
Steve Strazza | Chief Market Strategist, All Star Charts |
|
|
All Star Charts emails are a financial publication of general circulation and only offers impersonal advice, not tailored to individual needs of a specific client or group. Any comments or statements made herein do not necessarily reflect those of All Star Charts or its affiliates (collectively, "All Star Charts") and do not constitute buy or sell recommendations. Unless specifically indicated, this message is not an official confirmation of any transaction. The contents of any email communications to or from All Star Charts may be monitored or reviewed at All Star Charts's discretion. All Star Charts accepts no responsibility for any loss or damage arising in any way from the use of this transmission and any attachments; it is the responsibility of the recipient to ensure that they are virus free. If you reply to this email, please note that we are a public investor and do not want any material non-public information. We do not agree to keep confidential any information you provide and do not agree to any restrictions on our trading activity, except pursuant to a written confidentiality agreement executed by All Star Charts. |
Want to change how you receive these emails? You can manage your preferences here unsubscribe . © 2025 All Star Charts |
|
|
|
